LI
SLDB icon

Leap Investments’s Solid Biosciences SLDB Stock Holding History

Leap Investments’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,317
Closed -$221K – 542
2019
Q4 		$221K Buy
+3,317
New +$366K 0.1% 307
2019
Q3 		– Sell
-1,544
Closed -$133K – 479
2019
Q2 		$133K Buy
+1,544
New +$168K 0.18% 190

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Leap Investments's SLDB Position: Q1 2020 in Review

Leap Investments sold out of Solid Biosciences (SLDB) in Q1 2020, closing a stake of 3,317 shares — an estimated $221K sold.

Leap Investments first reported a position in SLDB in Q2 2019 and held it in 2 quarters. The position peaked at $221K in Q4 2019. 71 funds tracked by Wall St. Rank hold SLDB as of Q1 2020.

  • Leap Investments reported no remaining Solid Biosciences position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 3,317 Solid Biosciences shares in Q1 2020, an estimated $221K.
  • Leap Investments first reported a position in Solid Biosciences in Q2 2019 and held it in 2 quarters.
  • Leap Investments's Solid Biosciences position peaked at $221K in Q4 2019.
  • 71 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.